AGTC Leadership to Present at Upcoming Scientific and Investor Conferences

GAINESVILLE, Fla., Feb. 25, 2015 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced that company management will present at four upcoming scientific and investor conferences.

  • 27th Annual ROTH Conference – Dana Point, Calif. (March 8-11)
    On Tuesday, March 10th at 10:30am PT (1:30pm ET), Larry Bullock, Chief Financial Officer, will deliver a corporate overview discussing the company's lead programs in ophthalmology, including X-linked Retinoschisis (XLRS), Achromatopsia (ACHM) and X-linked Retinitis Pigmentosa (XLRP). To access a live webcast of this presentation, please visit A replay will be available for one month following the conference.
  • International Society for BioProcess Technology (ISBioTech) 5th Spring Meeting – Washington, D.C. (March 9-11)
    On Wednesday, March 11th at 8:30am ET, David Knop, Ph.D., Senior Director of Process Development, will represent AGTC during a presentation entitled "AAV Manufacturing Using Herpes-Assisted Vector Expansion." Dr. Knop will provide an overview of the company's proprietary AAV-based manufacturing platform, highlighting the proven safety and scalability of this technology.
  • 7th Ocular Diseases Drug Discovery Conference – San Diego, Calif. (March 19-20)
    Jeff Chulay, M.D., DTM&H, Chief Medical Officer, will lead a session entitled, "AAV-Based Gene Therapies for Orphan Ocular Disorders," on Friday, March 20th at 2:00pm PT (5:00pm ET) where he will discuss AAV vectors in the context of emerging genetic treatments for rare eye disorders. Dr. Chulay will address current investigational AAV-based therapies for diseases including XLRS, ACHM and XLRP. He will also discuss the current state of preclinical models and vector delivery as well as an approach to designing clinical trials for inherited orphan diseases in ophthalmology.
  • Alliance for Regenerative Medicine's 3rd Annual Regen Med Investor Day – New York, NY (March 25)
    Sue Washer, President and CEO, will provide a company presentation on March 25th at 2:10pm ET. Ms. Washer will discuss key corporate milestones in addition to providing an update on AGTC's clinical pipeline. To access a live webcast of this presentation, please visit A replay will be available at the same address shortly after the conference.

About AGTC

AGTC is a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop products designed to transform the lives of patients with severe diseases in ophthalmology. AGTC's lead product candidates focus on X-linked retinoschisis, achromatopsia and X-linked retinitis pigmentosa, which are inherited orphan diseases of the eye, caused by mutations in single genes that significantly affect visual function and currently lack effective medical treatments. AGTC is also pursuing pre-clinical development of treatments for wet AMD using the company's experience in ophthalmology to expand into disease indications with larger markets.

About X-linked Retinoschisis (XLRS)

XLRS is an inherited retinal disease caused by mutations in the RS1 gene, which encodes the retinoschisin protein. It is characterized by abnormal splitting of the layers of the retina, resulting in poor visual acuity in young boys, which can progress to legal blindness in adult men.

About Achromatopsia (ACHM)

ACHM is an inherited retinal disease, which is present from birth and is characterized by the lack of cone photoreceptor function. The condition results in markedly reduced visual acuity light sensitivity causing day blindness, and complete loss of color discrimination. Best-corrected visual acuity in persons affected by ACHM, even under subdued light conditions, is usually about 20/200, a level at which people are considered legally blind.

About X-linked Retinitis Pigmentosa (XLRP)

XLRP is an inherited condition that causes boys to develop night blindness by the time they are ten and progresses to legal blindness by their early forties.

CONTACT: David Carey Lazar Partners Ltd. T: (212) 867-1768 Corporate Contact: Larry Bullock Chief Financial Officer Applied Genetic Technologies Corporation T: (386) 462-2204

Source:Applied Genetic Technologies